Vimarsana
Biggest News Aggregation in the World

Page 8 - Scott Struthers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scott Struthers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scott Struthers Today - Breaking & Trending Today

Bourgeon Capital Management LLC Grows Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Vimarsana News

Bourgeon Capital Management LLC Grows Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Bourgeon Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 56.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,150 shares of the company’s stock after buying an additional 1,500 shares during the quarter. […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $1,040,500.00 in Stock - Vimarsana News

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $1,040,500.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) CEO Richard Scott Struthers sold 50,000 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the sale, the chief executive officer now owns 680,805 shares in the company, […]

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.5% After Insider Selling - Vimarsana News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.5% After Insider Selling

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating)’s share price traded down 5.5% during trading on Thursday following insider selling activity. The company traded as low as $18.58 and last traded at $18.62. 204,711 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 444,003 shares. The stock had previously […]

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 - Vimarsana News

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from... | June 21, 2023

Top in endocrinology: Testosterone replacement; lower long COVID risk in metformin users - Vimarsana News

Top in endocrinology: Testosterone replacement; lower long COVID risk in metformin users

In the TRAVERSE trial, men with hypogonadism at high risk for CVD who received testosterone had a similar risk for major adverse cardiovascular events compared with those who received placebo. A. Michael Lincoff, MD, vice chair for research, cardiovascular medicine and professor of medicine at Cleveland Clinic, said during a presentation at ENDO 2023 that the findings “should

Source: healio.com